Summit Therapeutics Inc.
About Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2024
- $0
- Net income
- -$1.1B
- Total assets
- $751.2M
- Market cap
- $11.5B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $1.1B
- Income tax
- $0
- Net income
- -$1.1B
- EPS (basic)
- $-1.44
- EPS (diluted)
- $-1.44
Balance sheet
- Total assets
- $751.2M
- Current assets
- $720.3M
- Total liabilities
- $92.3M
- Current liabilities
- $73.0M
- Shareholders’ equity
- $658.9M
Cash flow
- Operating cash flow
- -$322.9M
- Investing cash flow
- -$174.3M
- Financing cash flow
- $617.5M
- Net cash flow
- $120.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.5B
- EPS (diluted)
- $-1.44
- Shares outstanding
- 812.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 5, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.1B in FY2024.
- Trading 52% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Summit Therapeutics Inc..
Write a review
News about Summit Therapeutics Inc.
News & sentiment via Polygon.io
